ReviewBioengineering (Basel, Switzerland)2025
Smart Antidiabetic Nanomedicine: A Revolutionized Therapeutic Approach for Treatment of Diabetes Mellitus.
Review in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus affects over 530 million adults globally, with current therapies limited by frequent dosing, <20% oral bioavailability, and poor long-term glycemic control. Nanomedicine, particularly self-assembled peptide nanostructures (nanofibrils), offers sustained, glucose-responsive drug release and extended peptide bioactivity for several days per dose. This review critically evaluates recent advances in smart antidiabetic nanomedicine, focusing on quantitative improvements in pharmacokinetics, controlled release, and patient compliance compared with conventional treatments. It also outlines remaining challenges in large-scale synthesis, safety validation, and regulatory translation. Collectively, these insights highlight the potential of reversible peptide nanofibrils as long-acting, cost-effective therapeutics for improved diabetes management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.